MedPath

Transversus Thoracis Muscle Plane Block Plus Rectus Sheath Block in the Perioperative Pain Management of Cardiac Surgery

Not Applicable
Conditions
Coronary Artery Bypass Grafting or Heart Valve Surgery Via Median Sternotomy
Registration Number
NCT04838132
Lead Sponsor
Guangzhou First People's Hospital
Brief Summary

An emerging regional block technique, transverse thoracic muscle block covers the T2-T6 intercostal nerves and can effectively relieve perioperative pain during median sternotomy. Bilateral transverse thoracic muscle plane( TTP) block is expected to be a new analgesic mode in perioperative of cardiac surgery via sternotomy.

Detailed Description

This is a single-center, randomized, double-blind, parallel controlled clinical trial. Eighty patients planning to undergo coronary artery bypass grafting or heart valve surgery via median sternotomy were randomly assigned 1:1 to the experimental group or control group. After general anesthesia, all subjects were injected with 0.3% ropivacaine (experimental group) or 0.9% normal saline (control group) 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound by anesthesiologist. The main outcome indicators were the threshold of incision pain and the total amount of analgesics used during the operation and 48h after the operation. Secondary outcome measures were as follows: postoperative VAS score, duration of mechanical ventilation, days in ICU, total days of hospitalization, and hospitalization cost. This study will provide evidence-based medical evidence and clinical data support for the application of TTP block in cardiac surgery.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Patients voluntarily cooperate with the study and sign an informed consent form;
  • Ages between 18 and 65;
  • American Society of Anesthesiologists (ASA) classification: I-III;
  • Undergo coronary artery bypass grafting (CABG) or heart valve surgery with midsternal incision.
Exclusion Criteria
  • Refuse to participate in the trial;
  • Allergic to the anesthetics or analgesics;
  • Suffering with serious systemic diseases (kidney, liver, lungs and endocrine system);
  • American Association of Anesthesiologists (ASA) classification: IV-V;
  • Unstable hemodynamics;
  • History of drug abuse or chronic pain;
  • Mental disorders or communication difficulties;
  • Died during or immediately after the operation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Incidence of hyperalgesiaSurgery to 48 hours after

a 180mN von-Frey wire (Touch Test™ Sensory Evaluator, USA) was used to test the pain sensitivity of the area around the wound

The total amount of analgesics used in the perioperative period.Surgery to 48 hours after

During the perioperation, the amount of analgesics during the operation, the total amount of analgesic pump drugs used and the frequency of pressing the additional bolus trigger in the patient's analgesia system at 48 hours after the operation, and the amount of remedial analgesics

Secondary Outcome Measures
NameTimeMethod
Length of stay in hospitalthe day before hospital discharge

record how many days doses the patient spends in hospital

Visual Analogue ScaleExtubation to 24 hours after

A scale with a length of about 10cm is used. One side is marked with 10 scales, and the two ends are marked with "0" and "10" points respectively. 0 points mean painless, and 10 points mean the most intense pain that is unbearable

Postoperative complicationsthe day before hospital discharge

such as nausea and vomiting, pulmonary infection, wound infection, delayed healing, renal insufficiency, etc.

incidence of postoperative deliriumDay 7 after operation

Changes in postoperative state of consciousness were assessed

Trial Locations

Locations (1)

Guangzhou First People's Hospital

🇨🇳

Guangzhou, Guangdong, China

Guangzhou First People's Hospital
🇨🇳Guangzhou, Guangdong, China
Jierong Luo, MD
Sub Investigator
Bin Zheng, MD
Principal Investigator
Guokun Ou, MD
Sub Investigator
Haitao Zhou, MD
Sub Investigator
Xiaoqing Xie, MD, Msc
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.